You are leaving this site You are about to leave www.grantformultiplesclerosisinnovation.org/. The content of the site you are about to visit is not controlled by www.grantformultiplesclerosisinnovation.org/.
Rayaz Malik graduated in Medicine from the University of Aberdeen in 1991, obtained his MRCP in 1996, PhD from the University of Manchester in 1997 and was elected to become a fellow of the Royal College of Physicians in 2007. He was appointed as Consultant Physician and Senior Lecturer in 2001 and as Professor of Medicine and Consultant Physician in 2008 in Central Manchester University Teaching Hospitals and the University of Manchester. He was appointed as Professor of Medicine at Weill Cornell Medicine in 2014 and remains an honorary Professor of Medicine and Consultant Physician in Manchester.
Professor Malik was the President of Neurodiab (the diabetic neuropathy study group of the EASD) from 2009-2012. He is an associate editor for Diabetic Medicine (2006 to present); J of Diabetes and its Complications (2012-present) BMC Neurology (2009-present) and Advances in Therapy (2009-present). He is on the Juvenile Diabetes Research Foundation Complications and Clinical Investigation Research Committee (2005-present) and served on the MRC Clinical Translational research panel from 2012-2014.
His research focuses on the pathogenesis, assessment and treatment of diabetic neuropathy and cardiomyopathy, which is funded by the NIH, JDRF and QF. He was called to provide expert advice to NICE on diabetic gastroparesis and painful diabetic neuropathy in 2014.
GMSI project description:
Corneal confocal microscopy in multiple sclerosis
Axonal degeneration is a consistent feature of MS lesions and is known to occur early in the disease course, associated with significant disability and a poor prognosis
A major challenge in MS treatment is how to accurately monitor this axonal loss occurring in the brain, risk-stratify patients and monitor treatment efficacy.
The human eye offers an accessible site to study neurodegeneration and recent evidence suggests that quantification of the peripapillary retinal nerve fiber layer (pRNFL) thickness by optical coherence tomography (OCT) may have use as a biomarker of axonal loss in MS.
In previous work, we have demonstrated the utility of corneal confocal microscopy (CCM), a rapid non-invasive ophthalmic imaging modality, as a surrogate endpoint of peripheral neuropathy. In this study we aim to determine whether axonal loss detected with CCM, is related to clinical disability in patients with RRMS and PPMS. Furthermore, we will quantify these changes over time and investigate whether this correlates with disease progression and brain atrophy.